PPAR-gamma AGONIST FOR TREATMENT OF BLOOD CANCERS
Methods of treatment of blood cancers including leukemia and myeloma with the compound of formula (I) known as INT131:
1 . A method of treating a blood cancer selected from leukemia and myeloma in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
2 . The method of claim 1 , wherein the blood cancer is leukemia.
3 . The method of claim 2 , wherein the leukemia is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.
4 . The method of claim 1 , wherein the blood cancer is myeloma.
5 . The method of claim 4 , wherein the myeloma is selected from the group consisting of multiple myeloma, localized myeloma, plasmacytoma and extramedullary myeloma.
6 . The method of claim 1 , wherein the compound of formula (I) is in the form of a besylate salt.
7 . The method of claim 1 , wherein the therapeutically effective amount is from about 0.1 to about 10 milligrams.
8 . The method of claim 7 , wherein the therapeutically effective amount is from about 1 to about 4 milligrams.
9 . The method of claim 8 , wherein the therapeutically effective amount is from about 2 to about 3 milligrams.
10 . The method of claim 9 , wherein the therapeutically effective amount is about 3 milligrams.
11 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
12 . The method of claim 11 , wherein the pharmaceutical composition is administered to the subject daily.
13 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
14 . A method of treating the symptoms of leukemia in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
15 . The method of claim 14 , wherein the leukemia is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.
16 . The method of claim 21 , wherein the compound of formula (I) is in the form of a besylate salt.
17 . The method of claim 21 , wherein the therapeutically effective amount is from about 0.1 to about 10 milligrams.
18 . The method of claim 17 , wherein the therapeutically effective amount is from about 1 to about 4 milligrams.
19 . The method of claim 18 , wherein the therapeutically effective amount is from about 2 to about 3 milligrams.
20 . The method of claim 19 , wherein the therapeutically effective amount is about 3 milligrams.
21 . The method of claim 21 , wherein the pharmaceutical composition is administered to the subject twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
22 . The method of claim 21 , wherein the pharmaceutical composition is administered to the subject daily.
23 . The method of claim 21 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
24 . A method of treating the symptoms of myeloma in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
25 . The method of claim 24 , wherein the myeloma is selected from the group consisting of multiple myeloma, localized myeloma, plasmacytoma and extramedullary myeloma.
26 . The method of claim 42 , wherein the compound of formula (I) is in the form of a besylate salt.
27 . The method of claim 42 , wherein the therapeutically effective amount is from about 0.1 to about 10 milligrams.
28 . The method of claim 27 , wherein the therapeutically effective amount is from about 1 to about 4 milligrams.
29 . The method of claim 28 , wherein the therapeutically effective amount is from about 2 to about 3 milligrams.
30 . The method of claim 29 , wherein the therapeutically effective amount is about 3 milligrams.
31 . The method of claim 42 , wherein the pharmaceutical composition is administered to the subject twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
32 . The method of claim 31 , wherein the pharmaceutical composition is administered to the subject daily.
33 . The method of claim 42 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
34 . A method of treating a blood cancer selected from leukemia and myeloma in a subject in need thereof comprising increasing the serum adiponectin level in the subject by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
35 . The method of claim 34 , wherein the blood cancer is leukemia.
36 . The method of claim 35 , wherein the leukemia is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.
37 . The method of claim 34 , wherein the blood cancer is myeloma.
38 . The method of claim 37 , wherein the myeloma is selected from the group consisting of multiple myeloma, localized myeloma, plasmacytoma and extramedullary myeloma.
39 . The method of claim 34 , wherein the compound of formula (I) is in the form of a besylate salt.
40 . The method of claim 34 , wherein the therapeutically effective amount is from about 0.1 to about 10 milligrams.
41 . The method of claim 40 , wherein the therapeutically effective amount is from about 1 to about 4 milligrams.
42 . The method of claim 41 , wherein the therapeutically effective amount is from about 2 to about 3 milligrams.
43 . The method of claim 42 , wherein the therapeutically effective amount is about 3 milligrams.
44 . The method of claim 34 , wherein the pharmaceutical composition is administered to the subject twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
45 . The method of claim 44 , wherein the pharmaceutical composition is administered to the subject daily.
46 . The method of claim 34 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
47 . The method of claim 63 , wherein the adiponectin level in the subject increases by at least about 30%, at least about 68%, at least about 175%, or at least about 200%.
48 . The method of claim 47 , wherein the adiponectin level in the subject increases by at least about 175%.
49 . A method of treating a blood cancer selected from leukemia and myeloma in a subject in need thereof comprising increasing the serum adiponectin level in the subject by daily administering to the subject a pharmaceutical composition comprising about 1 to about 4 milligrams of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
50 . The method of claim 49 , wherein the blood cancer is leukemia.
51 . The method of claim 50 , wherein the leukemia is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.
52 . The method of claim 49 , wherein the blood cancer is myeloma.
53 . The method of claim 52 , wherein the myeloma is selected from the group consisting of multiple myeloma, localized myeloma, plasmacytoma and extramedullary myeloma.
54 . The method of claim 49 , wherein the compound of formula (I) is in the form of a besylate salt.
55 . The method of claim 49 , wherein the therapeutically effective amount is from about 2 to about 3 milligrams.
56 . The method of claim 55 , wherein the therapeutically effective amount is about 3 milligrams.
57 . The method of claim 49 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
58 . The method of claim 63 , wherein the adiponectin level in the subject increases by at least about 30%, at least about 68%, at least about 175%, or at least about 200%.
59 . The method of claim 58 , wherein the adiponectin level in the subject increases by at least about 175%.